RA
Rosalind Advisors Portfolio holdings
AUM
$207M
This Quarter Return
+19.06%
1 Year Return
+62.29%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$151M
AUM Growth
+$151M
(+19%)
Cap. Flow
-$156M
Cap. Flow
% of AUM
-103.79%
Top 10 Holdings %
Top 10 Hldgs %
73%
Holding
44
New
3
Increased
10
Reduced
11
Closed
9
Top Buys
| 1 |
CorMedix
CRMD
|
$11.9M |
| 2 |
MediWound
MDWD
|
$2.07M |
| 3 |
Cellectar Biosciences
CLRB
|
$2.07M |
| 4 |
Myomo
MYO
|
$1.43M |
| 5 |
Owlet
OWLT
|
$1.21M |
Top Sells
| 1 |
CYBN
Cybin
CYBN
|
$162M |
| 2 |
Viridian Therapeutics
VRDN
|
$3.9M |
| 3 |
Clearside Biomedical
CLSD
|
$3.13M |
| 4 |
ABVX
Abivax
ABVX
|
$2.75M |
| 5 |
Trevi Therapeutics
TRVI
|
$2.14M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Delcath Systems
DCTH
$385M
| $21.2M | 13.57% | 2,650,389 | – | – |
|
|
2
Myomo
MYO
$39.7M
| $12.1M | 7.76% | 3,021,391 +356,392 | +13% | +$1.43M |
|
|
3
CorMedix
CRMD
$1.11B
| $11.9M | 7.63% | +1,475,000 | New | +$11.9M |
|
4
Abeona Therapeutics
ABEO
$350M
| $11.6M | 7.41% | 1,832,000 +82,000 | +5% | +$518K |
|
|
5
MediWound
MDWD
$182M
| $11.3M | 7.26% | 628,050 +114,560 | +22% | +$2.07M |
|
|
CYBN
6
Cybin
CYBN
$176M
| $9.56M | 6.12% | 1,075,105 -18,224,895 | -94% | -$162M |
|
7
Xeris Biopharma Holdings
XERS
$1.26B
| $8.85M | 5.67% | 3,104,995 -15,175 | -0.5% | -$43.2K |
|
|
VRNA
8
Verona Pharma
VRNA
$9.16B
| $7.91M | 5.07% | 275,000 +25,000 | +10% | +$719K |
|
|
9
Cellectar Biosciences
CLRB
$15.5M
| $7.86M | 5.03% | 3,671,550 +965,934 | +36% | +$2.07M |
|
10
Ocular Therapeutix
OCUL
$2.12B
| $7.7M | 4.93% | 885,000 +135,000 | +18% | +$1.17M |
|
11
InspireMD
NSPR
$102M
| $6.74M | 4.31% | 2,514,046 +405 | +0% | +$1.09K |
|
|
OPTN
12
DELISTED
OptiNose
OPTN
| $5.55M | 3.55% | 8,287,503 +740,355 | +10% | +$496K |
|
|
CMPS
13
Compass Pathways
CMPS
$424M
| $4.92M | 3.15% | 781,423 +47,423 | +6% | +$299K |
|
|
PROF
14
Profound Medical
PROF
$134M
| $3.87M | 2.48% | 485,973 -47,360 | -9% | -$377K |
|
15
KalVista Pharmaceuticals
KALV
$678M
| $3.52M | 2.25% | 303,864 -34,121 | -10% | -$395K |
|
|
16
Trevi Therapeutics
TRVI
$883M
| $2.51M | 1.6% | 750,000 -641,577 | -46% | -$2.14M |
|
17
Outlook Therapeutics
OTLK
$37.8M
| $2.4M | 1.54% | 450,000 | – | – |
|
18
PolyPid
PYPD
$53.3M
| $2.34M | 1.5% | 679,168 +262,368 | +63% | +$903K |
|
19
Veru
VERU
$47.6M
| $2.07M | 1.33% | 2,694,503 -1,500 | -0.1% | -$1.15K |
|
|
ABVX
20
Abivax
ABVX
$6.12B
| $1.61M | 1.03% | 139,983 -238,433 | -63% | -$2.75M |
|
|
21
Owlet
OWLT
$128M
| $1.21M | 0.78% | +270,000 | New | +$1.21M |
|
22
Kiora Pharmaceuticals
KPRX
$9.55M
| $935K | 0.6% | 255,555 | – | – |
|
23
Fortress Biotech
FBIO
$76.8M
| $727K | 0.47% | 502,828 -104,969 | -17% | -$152K |
|
24
Biofrontera
BFRI
$9.45M
| $659K | 0.42% | 495,490 -8,771 | -2% | -$11.7K |
|
25
Talphera
TLPH
$11.1M
| $650K | 0.42% | 758,966 | – | – |
|